The audit was conducted in accordance with the Declaration of Helsinki, and all patients provided written informed consent before data collection and analysis.
The clinical outcome indicators were taken from international guidelines, but considering that the consensus on some MBD therapeutic targets is not generalized 3 we let each dialysis centre choose between the 2003 Kidney Disease Outcomes Quality Initiative (KDOQI) and the 2009 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 4, 5 and declare the choice before the beginning of the audit. Compliance with prescribed treatments was evaluated by administration of the Simplified Medication Adherence Questionnaire (SMAQ) to each patient, a tool that has been previously validated in haemodialysis patients, 6 whereas compliance with dietary advice was evaluated after administration of individual questionnaires by attending physicians.
A total of 170 patients from 18 centres were audited. Patient characteristics are summarized in Table 1 : 45 patients (30%) were diabetic, whereas 16 (9.4%) had received previous kidney transplantation and 7 (4%) had undergone parathyroidectomy. In all, 153 (90%) patients underwent online haemodiafiltration three times weekly; the mean spKT/V was 1.64 ± 0.37 and dialysate calcium content was 1.5 mmol/l in 85.8% of the patients.
As shown in Table 1 , the average phosphate and calcium plasma levels were 1.38 ± 0.38 and 2.28 ± 0.21 mmol/l, achieving therapeutic targets (for phosphate: 1.13-1.78 mmol/l and for calcium: 2.1-2.37 mmol/l) in 59.4% and 68.2% of the cases, respectively.
The mean intact parathyroid hormone (iPTH) levels were 32.8 ± 35.1 pmol/l; the overall rate of patients achieving therapeutic target was 38.2% and this percentage increased to 64% in centres adopting the KDIGO guidelines (3/18 centres). In all, 28 patients (16.4%) achieved the calcium, phosphate and iPTH targets simultaneously.
Phosphate plasma levels were inversely correlated with age and spKT/V (r 2 0.07, P o0.001 and r 2 0.05, P o 0.005, respectively), whereas they were directly related to iPTH levels (r 2 0.05, P o0.005).
Moreover, phosphate was significantly higher in patients referring low adherence to diet compared with the more compliant subjects (1.48 ± 0.38 vs 1.28 ± 0.32 pmol/l, P o 0.005).
As shown in Table 2 , there was a strong correlation between compliance with medications and achievement of phosphate therapeutic targets, although phosphate control was not significantly associated with the P binders prescribed. Similarly, achievement of PTH target was not related with any particular drug prescribed to control hyperparathyroidism, and patients taking calcimimetics were less likely to have calcium levels within the recommended target.
Levels of MBD biochemical indicators were not related with the presence of diabetes, CCI, compliance to diet or dialysis-related factors.
Interestingly, not elderly patients (n = 62), when compared with patients ⩾ 65 years (n = 108), presented significantly higher phosphate and iPTH levels (1.48 ± 0.42 vs 1.27 ± 0.34 mmol/l, P o0.05 and 38.8 ± 35.41 vs 29.58 ± 35.09 pmol/l, P o0.05, respectively) and lower levels of CCI (3.5 ± 1.8 vs 4.3 ± 2.3, P o0.05). Moreover, these patients presented a lower grade of compliance with treatments (Fisher's exact test, P = 0.006) and a reduced probability to achieve an adequate phosphate control (Table 2) .
Although MBD in HD patients is the object of primary clinical and research interest, its prevention and treatment still remain unsatisfactory, and the rate of failure in controlling the disease is so high that it induces in care personnel some adaptive tolerance as if it were an unavoidable condition. 7 The results of the audit reported here confirm the high failure rate in the achievement of guideline targets, showing that only 16% of the evaluated patients presented with calcium, phosphate and PTH levels simultaneously controlled. Different reasons may account for the problem, including some differences in guidelines that depend on weak evidence and limited implementation. in fact, any therapy cannot be effective if it is refused or missed by the patient. Therefore, compliance has to be ranked as the first aim of therapeutic intervention and deserves to be treated as the objective of scientific research rather than a matter of good sensebased counselling. A trained multidisciplinary staff including physician, nurse, nutritionist, psychologist and professional education expert should be dedicated to increase the compliance in strict cooperation with family members. In addition, structured programmes should be designed to improve the compliance and their effectiveness should be tested in controlled prospective studies.
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